METHODS FOR RAPID FORENSIC DNA ANALYSIS

• US 20100184035A1
• Filed: 02/25/2008
• Published: 07/22/2010
• Est. Priority Date: 02/23/2007
• Status: Active Grant

• Current Assignee: Ibis Biosciences Incorporated
• Original Assignee: Ibis Biosciences Incorporated
• Inventors: Sannes-Lowery, Kristin, Hofstadler, Steven A., Hall, Thomas A.
• Granted Patent: US 8,871,471 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6872 involving mass spectrometry

Abstract

The present invention provides methods and primer pairs for rapid, high-resolution forensic analysis of DNA and STR-typing by using amplification and mass spectrometry, determining the molecular masses and calculating base compositions of amplification products and comparing the molecular masses with the molecular masses of theoretical amplicons indexed in a database.

Claims

1-115. -115. (canceled)

116. A method for STR typing comprising:

a) amplifying a nucleic acid from a sample with an oligonucleotide primer pair comprising a forward and a reverse primer, each between 13 and 40 nucleobases in length, wherein said forward primer and is configured to hybridize within a first conserved region of said nucleic acid and said reverse primer is configured to hybridize within a second conserved region of said nucleic acid, wherein said first and said second conserved regions flank a variable nucleic acid region comprising a STR locus, wherein said amplifying generates at least one amplification product that is between about 45 and about 200 nucleotides in length;

b) determining the molecular mass of at least one strand of said at least one amplification product by mass spectrometry; and

c) comparing said molecular mass to a molecular mass database comprising a plurality of molecular masses of a plurality of STR-identifying amplification products indexed to said oligonucleotide primer pair and to a reference allele corresponding to said STR locus, wherein a match between said determined molecular mass and a molecular mass comprised in said molecular mass database identifies an STR allele in said sample.

117. The method of claim 116 further comprising:

d) calculating the base composition of said at least one strand of said at least one amplification product using said determined molecular mass; and

e) comparing said calculated base composition to a base composition database comprising a plurality of base compositions of STR-identifying amplification products indexed to said oligonucleotide primer pair and to a reference allele that corresponds to said STR locus, wherein a match between said calculated base composition and a base composition comprised in said base composition database identifies an STR allele in said sample.

118. The method of claim 116 wherein no match is identified in step c), further comprising:

d) calculating the base composition of said at least one strand of said at least one amplification product using said determined molecular mass, wherein said calculated base composition identifies a previously unknown allele of said STR locus; and

e) indexing said calculated base composition to said oligonucleotide primer pair, said previously unknown allele, said determined molecular mass and said sample in a database.

119. The method of claim 116 wherein said variable nucleic acid region varies in nucleic acid sequence.

120. The method of claim 116 wherein said variable nucleic acid region varies in nucleic acid sequence among two or more alleles of said STR locus that comprise the same number of repeat units.

121. The method of claims 116 wherein said variable nucleic acid region varies in nucleic acid sequence among two or more same-length alleles of said STR locus.

122. The method of claim 116 further comprising f) determining that said sample is heterozygous at said STR locus.

123. The method of claim 122 wherein said sample has been previously characterized as homozygous for said STR locus.

124. The method of claims 116 wherein said identified STR allele comprises at least one SNP.

125. The method of claim 124 wherein said STR locus is D5S818 and said at least one SNP comprises a change from G to T or A to C, relative to a reference allele for said STR locus comprised in said database;

wherein said STR locus is D8S1179 and said at least one SNP comprises a change from G to A or T to C relative to a reference allele for said STR locus comprised in said database;

wherein said STR locus is vWA and said at least one SNP comprises a change from G to T, A to G, C to T, or A to C, relative to a reference allele for said STR locus comprised in said database;

wherein said STR locus is D13S317 and said at least one SNP comprises a change from A to T relative to a reference allele for said STR locus comprised in said database; and

/or wherein said STR locus is D7S820 and said at least one SNP comprises a change from T to A relative to a reference allele for said STR locus comprised in said database.

126. The method of claim 116, wherein said STR locus is THO1 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs:

8;

61, 9;

61, 8;

62, 9;

63, 9;

64, 9;

65, 9;

66, or 10;

67;

wherein said STR locus is TPOX and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

5;

56, 5;

57, 5;

58, 5;

59, 6;

56, 6;

57, 6;

58, 6;

59, or 7;

60;

wherein said STR locus is D8S1179 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

SEQ ID NOs;

28;

85, 29;

86. 30;

87, or 31;

88;

wherein said STR locus is D5S818 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with aprimer pair selected from the group consisting of SEQ ID NOs;

36;

94, 37;

95, 38;

96, 39;

97, or 40;

98;

wherein said STR locus is CSF1PO and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity a primer pair selected from the group consisting of SEQ ID NOs;

43;

102, 44;

103, 45;

103, 46;

104, 46;

103, or 47;

104;

wherein said STR locus is D7S820 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

32;

89, 32;

90, 33;

91, 34;

90, 34;

92, or 35;

93;

wherein said STR locus is D135317 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

22;

79, 23;

80, 24;

81, 25;

82, 26;

83, or 27;

84;

wherein said STR locus is D16S539 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

17;

74, 18;

75, 19;

76, 20;

77, or 21;

78;

wherein said STR locus is vWA and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

1;

52, 2;

53, 3;

54, or 4;

55;

wherein said STR locus is FGA and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

11;

68, 111;

119, 112;

120, or 12;

69;

wherein said STR locus is D21S11 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

13;

70, 109;

117, 110;

118, or 14;

71;

wherein said STR locus is D18S51 and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

15;

72, 15;

73, 113;

121, 114;

122, 16;

72, or 16;

73; and

/or wherein said STR locus is D3S and wherein said oligonucleotide primer pair comprises at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with a primer pair selected from the group consisting of SEQ ID NOs;

41;

99, 42;

100, 115;

123, 116;

124, or 42;

101.

127. The method of claim 116 further comprising repeating said steps using at least one additional oligonucleotide primer pair configured to hybridize to conserved regions that flank an STR locus selected from the group consisting of:

VWA, TPOX, THO1, FGA, D21S11, D18S51, D16S539, D13S317, D8S1179, D7S820, D5S818, D3S, and CSF1PO.

128. The method of claim 127 wherein said repeating of said steps is carried out in a multiplex reaction.

129. The method of claim 116 further comprising repeating said amplifying step with at least one additional oligonucleotide primer pair, wherein at least one of said at least one additional primer is configured to hybridize to conserved regions of the AMEL locus.

130. The method of claim 129 wherein said repeating of said amplifying step is carried out in a multiplex reaction.

131. A purified oligonucleotide primer pair configured to generate an amplification product that is between about 45 and about 200 nucleotides in length comprising a forward and a reverse primer, each between 13 and 40 nucleobases in length

wherein said forward primer is configured to hybridize within a first conserved region of a nucleic acid and said reverse primer is configured to hybridize within a second conserved region of said nucleic acid,

wherein said first and second conserved regions flank a variable nucleic acid region comprising an STR locus selected from the group consisting of:

VWA, TPOX, THO1, FGA, D21S11, D18S51, D16S539, D13S317, D8S1179, D7S820, D5S818, D3S, and CSF1PO,

said primer pair comprising at least 70%, at least 80%, at least 90%, at least 95% or at least 100% sequence identity with an oligonucleotide primer pair selected from the group consisting of SEQ ID NOs;

1;

52, 2;

53, 3;

54, 4;

55, 5;

56, 5;

57, 5;

58, 5;

59, 6;

56, 6;

57, 6;

58, 6;

59, 7;

60, 8;

61, 9;

61, 8;

62, 9;

63, 9;

64, 9;

65, 9;

66, 10;

67, 11;

68, 12;

69, 13;

70, 14;

71, 15;

72, 15;

73, 16;

72, 16;

73, 17;

74, 18;

75, 19;

76, 20;

77, 21;

78, 22;

79, 23;

80, 24;

81, 25;

82, 26;

83, 27;

84, 28;

85, 29;

86. 30;

87, 31;

88, 32;

89, 32;

90, 33;

91, 34;

90, 34;

92, 35;

93, 36;

94, 37;

95, 38;

96, 39;

97, 40;

98, 41;

99, 42;

100, 42;

101, 43;

102, 44;

103, 45;

103, 46;

104, 46;

103, 109;

117, 110;

118, 111;

119, 112;

120, 113;

121, 114;

122, 115;

123, 116;

124, or 47;

104.

132. A kit comprising the primer pair of claim 131 and at least one additional primer pair comprising a forward and a reverse primer configured to hybridize within conserved regions of a nucleic acid that flank a variable nucleic acid region of said nucleic acid comprising an STR locus selected from the group consisting of:

VWA, TPOX, THO1, FGA, D21S11, D18S51, D16S539, D13S317, D8S1179, D7S820, D5S818, D3S, and CSF1PO.

133. The kit of claim 131 further comprising an oligonucleotide primer pair configured to hybridize within an AMEL locus or to regions flanking an AMEL locus.

134. A kit for forensic analysis comprising at least two oligonucleotide primer pairs configured to generate one or more amplification products between about 45 and about 200 nucleotides in length comprising a forward and a reverse primer, wherein the first of said at least two oligonucleotide primer pairs comprises a first forward primer configured to hybridize within a first conserved region of said nucleic acid and a first reverse primer configured to hybridize within a second conserved region of said nucleic acid, wherein said first and second conserved regions flank a variable nucleic acid region comprising vWR, and wherein the second of said at least two oligonucleotide primer pairs is configured to hybridize within an AMEL locus or to regions flanking an AMEL locus.

135. The kit of claim 134 further comprising at least one additional primer pair configured to hybridize to conserved regions flanking an STR locus selected from the group consisting of TPOX, TH01, D8S1179 and D5S818.

136. The kit of claim 134 further comprising at least one additional primer pair configured to hybridize to conserved sequence regions flanking an STR locus selected from the group consisting of CSF1PO, D7S820, D13S317, and D16S539.